Prognostic Value of TLR7, and TLR7, and Serum level of IL-17 and IL-23 in COVID-19 Infection

Abstract

Background: In December 2019, Wuhan, China, had seen an uncommon outbreak of coronavirus disease 2019 (COVID-19), a form of viral infection with pneumonia that is brought on by coronavirus 2 causing severe acute respiratory syndrome (SARS-CoV2) due to Severe acute respiratory CoV-2 level of contagiousness and COVID-19 disease pandemic. Objective: The aim of the present study is to find out the role of of TLR7 gene expression in COVID- 19 patients and disease progression to use them as a prognostic biomarker, also evaluation serum levels of IL-17 and IL-23 in disease course of patients. Materials and Methods: a case control study have been conducted, blood Samples has been collected from hospitals in Dhi-Qar Health Department, COVID-19 isolation centers for those infected with COVID-19 disease. The patients were sub-divided into three groups: mild cases group (N: 50), sever cases group (N: 50), and third control group (N: 50). genomic RNA was extracted from blood for molecular assay to study the role of TLR7 and Enzyme linked immunosorbent assay(ELIZA)technique was used to detect serum level of IL-17 and IL-23 in COVID -19 patients. Results: higher significantly variation on median TLR7 fold change, the median TLR7 fold change in the severe group which was 69.04 (39.81), in the mild group which was 28.38 (38.62) and in the control group which was 1.84 (2.84) which were significant (p < 0.05). There was higher significantly variation on IL-17 and IL-23 level, change severity group was higher comparison in both the control with mild groups (p < 0.05). Conclusion: All these studded parameters show high sensitivity and specificity, thus, we can using them as a combination for prognostic value in COVID-19 patients.